New immune cell therapy targets relapsed leukemia and MDS

NCT ID NCT06552416

First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 27 times

Summary

This early-stage study tests a pre-made immune cell therapy (MT-401-OTS) for people aged 65+ with relapsed acute myeloid leukemia or high-risk myelodysplastic syndromes. The therapy uses donor T-cells designed to attack multiple cancer-related targets. The main goals are to check safety and find the right dose, with a focus on controlling the disease rather than curing it.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MDS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • City of Hope Center (City of Hope National Medical Center, City of Hope Medical Center)

    RECRUITING

    Duarte, California, 91006, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • KU Cancer Center

    RECRUITING

    Kansas City, Kansas, 66160, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Moffitt Cancer Center

    RECRUITING

    Tampa, Florida, 33612, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.